A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
The purpose of this study is to find out whether it is better to receive a new drug,
MEDI4736, or better to receive no further treatment after surgery (and possibly
chemotherapy) for lung cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society